Codexis partners Dishman and AMPAC Fine Chemicals
Codexis, a Californian biotechnology firm, has formed two separate pharmaceutical manufacturing partnerships with Dishman Pharmaceuticals and Chemicals and AMPAC Fine Chemicals (AFC), a subsidiary of American Pacific Corporation.
Codexis, a Californian biotechnology firm, has formed two separate pharmaceutical manufacturing partnerships with Dishman Pharmaceuticals and Chemicals and AMPAC Fine Chemicals (AFC), a subsidiary of American Pacific Corporation. The agreements expand the application of Codexis technology to a broadened pipeline of pharmaceutical products.
Under the agreements, Codexis will apply its biocatalyst technology to selected therapeutic products to reduce cost, increase manufacturing efficiency and lessen environmental impact.
Dishman, headquartered in Ahmedabad, India, is a global outsourcing partner manufacturing active pharmaceutical ingredients (APIs) and intermediates for the pharmaceutical industry.
The partnership covers the use of Codexis" proprietary enzymatic biocatalysis technology for the manufacture of building blocks, intermediates and APIs for pharmaceutical companies.
Dishman will be able to offer this technology to its own customers. In addition, the companies will work exclusively on certain accounts.
Codexis offers a wide range of enzymes for the pharmaceutical synthesis of chiral compounds.
Dishman operates 12 API and intermediate production facilities in India, China, Switzerland and the UK, manufacturing products for drug companies worldwide.
AFC, headquartered in Rancho Cordova, CA, is a custom manufacturer of pharmaceutical fine chemicals. The company specialises in technology using high energetic chemistry and other specific technologies.
"These new partnerships bring Codexis technology to an expanded portfolio of innovator pharmaceutical products. They will be important as we continue to serve our pharmaceutical customers worldwide," said Alan Shaw, Codexis president and chief executive.
